February 14, 2012
Seattle-based biotechnology company Cell Therapeutics Inc. agreed to pay $19 million to settle a class action by investors who contended the company's stock price was artificially inflated due to misleading statements about a pipeline drug, according to a Tuesday court filing.
February 07, 2011
A federal judge has refused to dismiss a consolidated class action accusing biopharmaceutical company Cell Therapeutics Inc. and its executives of misleading investors into believing the U.S. Food and Drug Administration was poised to approve a new cancer treatment product.